Clinical Trial: Clinical Experience With Sparsentan in Switzerland in IgA Nephropathy

U.S., April 30 -- ClinicalTrials.gov registry received information related to the study (NCT07555301) titled 'Clinical Experience With Sparsentan in Switzerland in IgA Nephropathy' on April 21.

Brief Summary: An observational study tracking the clinical course of patients with IgA nephropathy.

Study Start Date: June 01

Study Type: OBSERVATIONAL

Condition: IgA Nephropathy (IgAN)

Intervention: DRUG: sparsentan

Follow up observation of patients with IgA Nephropathy on sparsentan regarding Albuminuria and GFR

DRUG: sparsentan

follow up observation of Albuminuria and GFR in IgA patients in therapy with sparsentan

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Waid City Hospital, Zurich

Information provided by (Responsible Party): S...